Answers are grounded in this paper and cite their sources.
Recent surveillance from US hospitals shows that more than 99.5% of vancomycin-resistant enterococci (VRE) isolates remain susceptible to daptomycin. This report describes emergence of daptomycin-resistant VRE at a major cancer center. The percentage of patients with daptomycin-resistant VRE bacteremia increased from 3.4% in 2007 to 15.2% in 2009 ([Formula: see text]). Without susceptibility data, empiric daptomycin therapy for VRE infections should be used with caution.
No takes yet. Share an insight, caveat, or question.
Kamboj et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: